Impact of Tenofovir Alafenamide Vs. Entecavir on Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B

Hye Won Lee
Yonsei University College of Medicine

Young Youn Cho
Chung Ang University Hospital

Beom Kyung Kim (✉ beomkkim@yuhs.ac)
Yonsei University College of Medicine

Hyein Lee
Severance Hospital

Jae Seung Lee
Yonsei University College of Medicine

Seung Up Kim
Yonsei University College of Medicine

Jun Yong Park
Yonsei University College of Medicine

Do Young Kim
Yonsei University College of Medicine

Sang Hoon Ahn
Yonsei University College of Medicine

Soo Young Park
Kyungsung University

Research Article

**Keywords:** hepatitis, hepatitis B, chronic hepatitis B, entecavir, tenofovir alafenamide, hepatocellular carcinoma, risk, risk factor, prediction, prognosis

**DOI:** [https://doi.org/10.21203/rs.3.rs-466650/v1](https://doi.org/10.21203/rs.3.rs-466650/v1)

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](https://creativecommons.org/licenses/by/4.0/)
Abstract

Background & aims: Whether entecavir (ETV) or tenofovir alafenamid (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear. The present study was conducted to explore the ability of these two antivirals to prevent HCC.

Methods: From 2012 to 2019, treatment-naïve CHB patients undergoing ETV or TAF therapy were recruited at three academic teaching hospitals. The TAF group comprised patients starting TAF as first-line antiviral and those switching antivirals from tenofovir disoproxil fumarate to TAF. Patients with decompensated cirrhosis or HCC at enrollment were excluded from the analysis. Cumulative probabilities of HCC were assessed using the Kaplan-Meier method.

Results: In total, 1,810 patients (1,525 and 286 in ETV and TAF groups, respectively) were recruited. The annual HCC incidence was statistically not different between the ETV and TAF groups (1.67 vs. 1.19 per 100 person-years, respectively) with an adjusted hazard ratio (HR) of 0.681 ($p=0.255$), as determined by multivariate analysis. Male, hypertension, liver cirrhosis, FIB-4 index, and albumin were independent prognostic factors for HCC development. Propensity score-matched and inverse probability of treatment weighting analyses yielded similar results, with non-statistically different HCC incidence between the ETV and TAF groups (1.07 vs. 1.19 per 100 person-years (HR=0.973; $p=0.953$) and 1.67 vs. 1.89 per 100 person-years, respectively (HR=0.949; $p=0.743$).

Conclusions: These findings suggest that ETV- and TAF-treated CHB patients have similar risk of developing HCC. Further studies with the larger sample size and longer follow-up are needed to validate these results.

Introduction

Chronic hepatitis B virus (HBV) infection affects approximately 350 million people worldwide, and chronic hepatitis B (CHB) is endemic to East Asia. [1–5] Given the persistent intrahepatic replication status of HBV-DNA, HBV infection itself is significantly associated with increased risk of liver disease progression to cirrhosis and/or hepatocellular carcinoma (HCC). [6, 7] Therefore, replication-suppressing antiviral therapy with potent nucleos(t)ide analogues (NUCs) and high genetic barrier to resistance is recommended to patients with chronic HBV infection in order to prevent liver disease progression. [2] Nevertheless, as the HBV-DNA integrates into the host hepatocyte genome, the virus is rarely eradicated through long-term antiviral therapy, and most patients with CHB additionally require periodic HCC surveillance. [8, 9]

Recently, along with entecavir (ETV) and tenofovir disoproxil fumarate (TDF), tenofovir alafenamid (TAF) was accepted as first-line NUC for the treatment of older populations or patients with co-morbidities for renal or bone disease. This approval was based on the similar short to intermediate-term antiviral effects of these three agents in treatment-naïve CHB patients. [10, 11] Furthermore, effective rescue regimens may offset the potential hazard by suboptimal virological response or genotypic resistance even in a very
small proportion (approximately 1%) of patients treated with ETV. [12, 13] Accordingly, the long-term clinical efficacy for preventing the risk of liver disease progression to cirrhosis and/or HCC are expected to be similar among the regimens. Nevertheless, since Choi et al. [14] reported that TDF is associated with a significantly lower risk of HCC (hazard ratio [HR] = 0.61) and all-cause mortality or orthotopic liver transplant (HR = 0.77) than ETV, several studies were conducted to validate such phenomena. However, this issue remains controversial due to somewhat contradictory results among studies, including similar efficacy between patients receiving two antivirals, overall favorable outcomes among those treated with TDF, or discrepant results according to presence of cirrhosis or follow-up duration. [15–20] In addition, a more recent study based on data from two phase III clinical trials [21, 22] showed that patients treated with TAF showed a tendency for lower risk of HCC development, even though not statistically significant (p = 0.14), compared to those treated with TDF. [23]

The present large-scale, multicenter cohort study was conducted in three academic teaching hospitals in the Republic of Korea aiming to further explore the efficacy of ETV- and TAF-based treatment in treatment-naïve CHB patients, regarding the risk of HCC development.

**Methods**

**Subjects**

Treatment-naïve CHB patients who underwent antiviral therapy with either ETV 0.5 mg/day (ETV group) or TAF 25 mg/day-based regimen (TAF group) from 2012 to 2019 in three academic teaching hospitals (Yonsei University Severance Hospital, Kyungpook National University Hospital, and Chung Ang University Hospital) were consecutively screened for eligibility. TAF group comprised patients starting TAF as a first-line antiviral regimen as well as those who switched NUCs from the TDF to the TAF regimen. The inclusion criteria were as follows: (1) age ≥ 19 years, (2) well-preserved liver function, and (3) follow-up duration of at least 6 months. The exclusion criteria were as follows: (1) history of HCC at enrollment, (2) decompensated cirrhosis at enrollment, (3) change of antiviral from ETV to TDF or TAF, (4) change of antiviral from TDF or TAF to ETV, (5) coinfection with other hepatitis virus, (6) history of organ transplantation, (7) development of clinical events (HCC, death, or orthotopic liver transplant) within 6 months of enrollment, and (8) other significant medical illnesses. Owing to the homogenous nature of the study population, data on race/ethnicity were not collected.

In the Republic of Korea, the reimbursement criteria for ETV, TDF, or TAF are identical (Supplementary Table 1). If histologic information was not available, compensated cirrhosis was clinically defined according to the following criteria: (1) platelet count < 150,000/µL and ultrasonographic findings suggestive of compensated cirrhosis, including a blunted, nodular liver surface accompanied by splenomegaly (> 12 cm); or (2) esophageal or gastric varices.

The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of each participating institution.
Clinical evaluation, follow-up, and outcomes

During follow-up, all patients underwent routine blood-chemistry testing, and serum HBV-DNA levels and of other viral markers were assessed every 3–6 months. Patients also evaluated by ultrasonography and the serum levels of alphafetoprotein were determined every 6 months to screen for HCC and cirrhotic complications. [24–26]

The primary outcome of the study was HCC development, as diagnosed based on histological evidence or dynamic computed tomography, and/or magnetic resonance imaging findings (nodule > 1 cm with arterial hypervascularity and portal/delayed-phase washout). [27–30] The index date was the date of the first antiviral prescription and the time to HCC development was considered as the period between the index date and the date of HCC diagnosis or the end of follow-up in the absence of HCC development.

Statistical analysis

Data are expressed as means ± standard deviation or as numbers (%). Differences among continuous and categorical variables were examined for statistical significance using the Student’s t-test (or the Mann–Whitney test, if appropriate) and the chi-squared test (or Fisher’s exact test, if appropriate). The cumulative risk of HCC was calculated using the Kaplan–Meier method and was compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.

To reduce selection bias and the effect of potential confounders, propensity scores (PS) were calculated by logistic regression based on age, gender, diabetes, hypertension, compensated cirrhosis, hepatitis B e-antigen (HBeAg), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, and platelet count. Differences between the ETV and TAF groups were balanced by a 1:1 PS-matched and inverse probability of treatment weighting (IPTW) analyses.

All statistical analyses were conducted using the SAS (ver. 9.4; SAS Institute, Cary, NC, USA) and R software (V.3.4.4, http://cran.r-project.org/). Two-sided p-values < 0.05 were deemed statistically significant differences.

Results

Baseline characteristics

A total of 1,810 patients were included in the analyses, among whom 1,525 and 285 were comprised in the ETV and TAF groups, respectively. The baseline characteristics of the patients are listed in Table 1. Patients in the ETV group were older (52.3 vs. 49.5 years, p < 0.001) and a higher proportion of patients had diabetes (18.0% vs. 9.5%, p < 0.001) and hypertension (23.3% vs. 16.5%, p = 0.011) and a lower proportion were HBeAg-positive (34.3% vs. 56.8%, p < 0.001), compared to those in the TAF group, respectively. Moreover, the TAF group had higher mean platelet count (179.4 vs. 178.9 ´ 10^3/mL; p < 0.001) and albumin levels (4.1 vs. 4.0 g/dL, p < 0.001) and lower total bilirubin level (1.0 vs. 1.1 mg/dL, p < 0.001), compared to the ETV group, respectively. However, no significant difference in the proportion of...
males (60.0% vs. 59.6%, $p = 0.912$) and liver cirrhosis (29.0% vs. 33.7%; $p = 0.116$) was observed between the groups.

**Clinical outcomes and comparison of baseline characteristics between patients with HCC and those without**

Among the entire cohort, 89 (4.9%) patients developed HCC during follow-up, of whom 79 (5.2%) were in the ETV group and 10 (3.5%) were in the TAF group ($p = 0.231$). Patients with HCC were more likely to be older (56.9 vs. 52.1 years, $p < 0.001$) and male (83.1% vs. 58.7%, $p < 0.001$) and have hypertension (46.1% vs. 21.0%, $p < 0.001$), liver cirrhosis (48.3% vs. 28.8%, $p < 0.001$), and lower mean platelet counts (137 vs. 181 $\times 10^3$/mL, $p < 0.001$) compared to patients without HCC, respectively (**Supplementary Table 2**).

The cumulative risk of HCC development at 1, 3, and 5 years was 0.8%, 4.3%, and 10.7% (annual incidence, 1.67 per 100 person-years), respectively, in the ETV group; and 0.0%, 1.4%, and 10.6% (annual incidence, 1.19 per 100 person-years), respectively, in the TAF group ($p = 0.252$ (**Figure 1**), representing a HR (reference: ETV group) of 0.681 (95% confidence interval [CI]: 0.351–1.320; $p = 0.255$).

**Prognostic factors affecting HCC development**

**Table 2** shows the potential risk factor for HCC development. Male, diabetes, hypertension, liver cirrhosis, FIB-4 index, and albumin levels, but not TAF group, proved to be significant risk factors for HCC development according to univariate analysis. After adjusting such significant univariate predictors, the risk of HCC was not statistically different between the two groups (adjusted HR = 0.646 [95% CI: 0.331–1.258]; $p = 0.198$).

Next, these identified potential risk predictors were further assessed by multivariate analysis, which revealed that male (adjusted HR = 3.796 [2.159–6.674]; $p < 0.001$), hypertension (adjusted HR = 3.042 [1.935–4.783]; $p < 0.001$), liver cirrhosis (adjusted HR = 1.801 [1.184–2.739]; $p = 0.006$), FIB-4 index (adjusted HR = 1.084 [1.029–1.142]; $p = 0.002$), and albumin (adjusted HR = 0.954 [0.633–1.438], $p = 0.823$) were the independent prognostic factors for HCC development.

**Clinical outcomes after adjustment by PS-matching**

The 1:1 PS-matched analysis generated 285 pairs, of which the standardized mean differences of all variables converged upon almost 0.1 (**Supplementary Figure 1**), suggesting the appropriate balancing of the variables between the ETV and TAF groups. The baseline characteristics of the two groups are described in **Table 3**. No significant difference in any variables were observed between the groups (all $p > 0.05$), except for AST and ALT levels (both $p < 0.001$). The cumulative risk of HCC development at 1, 3, and 5 years was of 0.7%, 2.6%, and 5.8% (annual incidence: 1.07 per 100 person-years) in the ETV group and was 0.0%, 1.3%, and 10.6% (annual incidence: 1.19 per 100 person-years) in the TAF group (**Figure 2**: $p = 0.952$), respectively, representing a HR of 0.973 [95% CI: 0.400–2.368] ($p = 0.953$).
Clinical outcomes after adjustment by IPTW

The standardized mean differences of all variables after IPTW also converged upon almost 0.1 (Supplementary Figure 2), suggesting the appropriate balancing of the variables between the ETV and TAF groups. The baseline characteristics of the two groups were described in Table 4. No significant differences were observed for most variables between the ETV and TAF groups (all $p > 0.05$), except for age ($p < 0.001$), liver cirrhosis ($p = 0.034$), and the levels of AST ($p < 0.001$), ALT ($p < 0.001$), total bilirubin ($p = 0.040$), and albumin ($p = 0.001$). The cumulative risk of HCC development at 1, 3, and 5 years was of 0.8%, 4.3%, and 10.6% (annual incidence: 1.67 per 100 person-years) in the ETV group and 0.0%, 2.7%, and 17.2% (annual incidence: 1.89 per 100 person-years), in the TAF group (Figure 3; $p = 0.869$), respectively, representing a HR of 0.949 [95% CI: 0.696–1.295] ($p = 0.743$).

Discussion

The current guidelines recommend ETV, TDF, or TAF as first-line NUCs against chronic HBV infection, based on similar efficacies of virological, serological, and biochemical response. [2, 3] Of these, considering renal and bone safety during long-term NUC therapy, ETV or TAF might be preferred for the treatment of the so-called “high-risk” patients. In line with the ongoing controversy about which is better between ETV vs. TDF for preventing HCC development, the most recent study showed a trend that TAF has a more favorable preventive effect than TDF. [23] Given the poor prognosis of HCC, determining the treatment of choice for patients with CHB could become a scientifically, socio-economically, and ethically important matter. Hence, in our independent, large-scale, multi-center cohort study, this issue was addressed.

The present study showed that prescribing TAF as a first-line NUCs or switching NUCs from TDF to TAF did not provide a statistically significant benefit over long-term ETV as a first-line treatment, as demonstrated by the comparable clinical outcomes regarding HCC development in all the analyses performed (including not only unadjusted analysis but also multivariate, PS-matched, and IPTW analyses; all $p > 0.05$). This study had several strengths. First, the large sample of approximately 1,800 patients from three independent academic teaching hospitals enhanced the reliability of the results. Considering that TAF has been officially reimbursed by the National Health Insurance Service of the Republic of Korea since November 2017, the relatively sufficient number of HCC cases (4.3%) with a median follow-up period of 35.7 months in the present study contrast with the 1.3% HCC incidence reported by Lim et al., [23] thereby providing adequate statistical power to address this issue. [29] Second, in order to minimize the confounding effects through the change of medication from ETV to TDF/TAF, or vice-versa, owing to poor compliance from adverse events or sub-optimal virological response, we excluded such patients. Indeed, Lim et al. [23] did not show also the statistical significance between the two groups ($p = 0.14$). Nevertheless, it is noteworthy that their Kaplan-Meier curves of the two groups did not cross each other during the whole follow-up period, [23] suggesting a possibility of positive results in a future study with a larger sample size and longer follow-up. One of the most plausible hypotheses explaining such a trend of the favorable outcome in patients treated with TAF is that they are more likely to achieve the
normalization of ALT than those receiving ETV or TDF, [10, 21, 22] given that on-treatment ALT normalization is associated with a lower risk of HCC development. [31–33] However, since the upper limit of normal value varies among studies and/or local laboratories and the ALT normalization itself is closely associated with various factors such as age, gender, steatosis, metabolic syndrome, alcohol use, and other medications that can potentially affect the long-term prognosis, further studies are required to draw a thorough conclusion. The carcinogenic potential of ETV and the induction of interferon (IFN)-λ3 production by tenofovir might in part explain the favorable outcome by TAF in comparison with ETV. However, such hypotheses are also still problematic. First, ETV was reported to increase the incidence of lung adenomas and carcinomas, HCC, and vascular tumors in mice at 4 mg/kg; and of HCC, brain microglial tumors, and skin fibroma in rats at 1.4–2.6 mg/kg. [34] However, these dosages are at least 100fold higher than those used in humans. In contrast, two recent large-scale real-life studies reported that long-term ETV therapy does not increase the risk of cancer. [35, 36] Moreover, in the long-term follow-up study by Kim et al. [37], the incidence of HCC was statistically not different during and after the first 5 years of ETV treatment (2.29% vs. 1.66%, p = 0.22). If long-term ETV maintenance retained significant pro-carcinogenic effects for humans, the HCC incidence would have progressed rapidly with time. In addition, although IFN-λ3 production might be induced by long-term TDF therapy, [27] conflicting data have also been reported. [28, 38–41] Because IFN-λ assays have not been standardized, neither its anti-carcinogenic effect in the human liver nor the causality of the relationship between higher IFN-λ3 levels and lower incidence of HCC has been confirmed.

This study also had some limitations. First, since TAF has been officially reimbursed by the National Health Insurance Service in the Republic of Korea since November 2017, a relatively small proportion of patients treated with TAF was available, and their follow-up data was not adequate to observe a sufficient number of liver-related events, which may introduce selection bias, particularly regarding treatment allocation. To overcome this, various statistical adjustments were performed, as well as subgroup analyses, which confirmed the reproducibility of the results. Nevertheless, a prospective cohort study of the association between antiviral type and HCC risk with long-term follow-up is needed. Second, most of our study population (> 98%) was infected with HBV genotype C through vertical transmission, which was significantly associated with the increased probability of HCC occurrence. [42–45] Thus, our results may not be representative of the full spectrum of the CHB population. However, given that the overall virological response rates by oral NUCs are similar across various HBV genotypes in contrast to pegylated interferon therapy, [42] it is possible that the present results would be largely maintained in different study populations. Lastly, the use of new biomarkers (e.g. serum quantitative HBsAg, serum hepatitis B core-related antigen, serum HBV-RNA, or specific HBV mutants) that could reflect the clinical course of CHB would have allowed more detailed analyses. [46–51]

In conclusion, the overall prognosis regarding HCC development was not statistically different between patients treated with ETV or TAF. Because prevention of liver-disease progression by appropriate antiviral therapy is a very important medical and socio-economical issue, further studies with long-term follow-up are needed to validate these results.
List Of Abbreviations

HBV, hepatitis B virus; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; NUC, nucleos(t)ide analogue; ETV, entecavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; HR, hazard ratio; PS, propensity scores; HBeAg, hepatitis B e-antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IPTW, inverse probability of treatment weighting.

Declarations

- Data Availability: Yes
- Animal Research (Ethics): N/A
- Consent to Participate (Ethics): N/A
- Consent to Publish (Ethics): N/A
- Plant Reproducibility: N/A
- Clinical Trials Registration: N/A
- Author Contribution: All authors conceived and designed the study. HL conducted statistical analyses, and all authors interpreted the findings. HWL, YYC, BKK, and SYP drafted the manuscript. HL, JSL, SUK, JYP, DYK and SHA critically reviewed the manuscript for key intellectual content. All authors approved the final manuscript. HCK and SUK are the guarantors, and as such, had full access to the data and take responsibility for its integrity and accuracy.
- Conflict of Interest: No
- Funding: This study was supported by a faculty research grant of Yonsei University College of Medicine for (6-2020-0130).

References

1. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93-159. [https://doi.org/10.3350/cmh.2019.1002](https://doi.org/10.3350/cmh.2019.1002)
2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. [https://doi.org/10.1016/j.jhep.2017.03.021](https://doi.org/10.1016/j.jhep.2017.03.021)
3. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. [https://doi.org/10.1002/hep.29800](https://doi.org/10.1002/hep.29800)
4. Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26(4):411-429. [https://doi.org/10.3350/cmh.2020.0049](https://doi.org/10.3350/cmh.2020.0049)
5. Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol. 2020;26(2):209-215. [https://doi.org/10.3350/cmh.2019.0065](https://doi.org/10.3350/cmh.2019.0065)
6. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678-686. https://doi.org/10.1053/j.gastro.2005.11.016

7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama. 2006;295(1):65-73. https://doi.org/10.1001/jama.295.1.65

8. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer BA, Ferlitsch A, et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int. 2015;35(2):381-390. https://doi.org/10.1111/liv.12623

9. Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61(6):1851-1859. https://doi.org/10.1002/hep.27735

10. Con D, Goodwin T, Majeed A, Roberts S, Kemp W. Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis. J Viral Hepat. 2021;28(1):40-50. https://doi.org/10.1111/jvh.13400

11. Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5(5):441-453. https://doi.org/10.1016/s2468-1253(19)30421-2

12. Yim SY, Um SH, Jung JY, Seo YS, Yim HJ, Ryu HS, et al. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus. J Clin Gastroenterol. 2014;48(2):166-171. https://doi.org/10.1097/MCG.0b013e3182a4711d

13. Liu J, Yang HI, Lee MH, Jen CL, Battrla-Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64(2):381-389. https://doi.org/10.1002/hep.28552

14. Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology. 2017;66(5):1454-1463. https://doi.org/10.1002/hep.29321

15. Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep. 2020;10(1):13537. https://doi.org/10.1038/s41598-020-70433-z

16. Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol. 2019;71(3):456-464. https://doi.org/10.1016/j.jhep.2019.03.028

17. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol. 2020;73(5):1037-1045. https://doi.org/10.1016/j.jhep.2020.06.011
18. Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2020;158(1):215-225 e216. https://doi.org/10.1053/j.gastro.2019.09.025

19. Cheung KS, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, et al. Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2020;11(10):e00236. https://doi.org/10.14309/ctg.0000000000000236

20. Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2020;69(7):1301-1308. https://doi.org/10.1136/gutjnl-2019-318947

21. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196-206. https://doi.org/10.1016/s2468-1253(16)30107-8

22. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185-195. https://doi.org/10.1016/s2468-1253(16)30024-3

23. Lim YS, Chan HL, Seto WK, Ning Q, Agarwal K, Janssen HLA, et al. Impact of treatment with tenofovir alafenamide or tenofovir disoproxil fumarate on hepatocellular carcinoma incidence in patients with chronic hepatitis B Hepatology. 2019;70(S1):126A.

24. Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26(1):54-59. https://doi.org/10.3350/cmh.2019.0039

25. Maruyama H, Kato N. Advances in ultrasound diagnosis in chronic liver diseases. Clin Mol Hepatol. 2019;25(2):160-167. https://doi.org/10.3350/cmh.2018.1013

26. Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25(4):335-343. https://doi.org/10.3350/cmh.2019.0010

27. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019

28. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380. https://doi.org/10.1002/hep.29086

29. Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol. 2020;26(3):340-351. https://doi.org/10.3350/cmh.2020.0004
30. Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol. 2019;25(3):223-233. https://doi.org/10.3350/cmh.2018.0107

31. Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol. 2020;115(3):406-414. https://doi.org/10.14309/ajg.0000000000000490

32. Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol. 2018;69(4):793-802. https://doi.org/10.1016/j.jhep.2018.05.009

33. Kim EJ, Yeon JE, Kwon OS, Lee HN, Shin SK, Kang SH, et al. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. Dig Dis Sci. 2017;62(3):808-816. https://doi.org/10.1007/s10620-016-4431-8

34. Laccetti M, Manes G, Uomo G, Lionello M, Rabitti PG, Balzano A. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis. 2000;32(4):335-338. https://doi.org/10.1016/s1590-8658(00)80027-4

35. Chao X, Qian H, Wang S, Fulte S, Ding WX. Autophagy and liver cancer. Clin Mol Hepatol. 2020;26(4):606-617. https://doi.org/10.3350/cmh.2020.0169

36. Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol. 2020;26(4):506-515. https://doi.org/10.3350/cmh.2020.0038

37. Kim BG, Park NH, Lee SB, Jeon S, Park JH, Jung SW, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B. Liver Int. 2018. https://doi.org/10.1111/liv.13938

38. Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology. 2015;62(3):694-701. https://doi.org/10.1002/hep.27889

39. Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, et al. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat. 2018;25(10):1161-1171. https://doi.org/10.1111/jvh.12927

40. Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020;26(3):364-375. https://doi.org/10.3350/cmh.2020.0012

41. Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69(2):278-285. https://doi.org/10.1016/j.jhep.2018.02.032

42. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16(8):1169-1186. https://doi.org/10.3851/imp1982
43. Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, et al. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol. 2020;11(3):e00140. https://doi.org/10.14309/ctg.00000000000000140

44. Kim SU, Seo YS, Lee HA, Kim MN, Lee EJ, Shin HJ, et al. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. Cancer Epidemiol Biomarkers Prev. 2020;29(4):832-837. https://doi.org/10.1158/1055-9965.Epi-19-0614

45. Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, et al. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol. 2019;10(6):e00036. https://doi.org/10.14309/ctg.0000000000000036

46. Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2019 69(4)(4):1816-1827. https://doi.org/10.1002/hep.30325

47. Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020;26(3):261-279. https://doi.org/10.3350/cmh.2020.0032

48. Lall S, Agarwala P, Kumar G, Sharma MK, Gupta E. The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer? Clin Mol Hepatol. 2020;26(2):187-195. https://doi.org/10.3350/cmh.2019.0060

49. Mak LY, Cloherty G, Wong DK, Gersch J, Seto WK, Fung J, et al. HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology. 2020. https://doi.org/10.1002/hep.31616

50. Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, Yang WT, et al. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology. 2019;157(6):1518-1529.e1513. https://doi.org/10.1053/j.gastro.2019.08.028

51. Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology. 2019;156(2):355-368.e353. https://doi.org/10.1053/j.gastro.2018.11.037

Tables
Table 1. Comparison of baseline characteristics between two groups among the entire population

| Variables                  | Total (N=1810) | ETV group (N=1525) | TAF group (N=285) | p-value |
|----------------------------|----------------|-------------------|-------------------|---------|
| Age, years                 | 52.8 ± 11.3    | 52.3 ± 11.4       | 49.5 ± 11.4       | <0.001  |
| Male, no. (%)              | 1085 (59.9)    | 915 (60.0)        | 170 (59.6)        | 0.912   |
| Diabetes                   | 301 (16.6)     | 274 (18.0)        | 27 (9.5)          | <0.001  |
| Hypertension               | 403 (22.3)     | 356 (23.3)        | 47 (16.5)         | 0.011   |
| Liver cirrhosis            | 539 (29.8)     | 443 (29.0)        | 96 (33.7)         | 0.116   |
| HBeAg positivity           | 685 (37.8)     | 523 (34.3)        | 162 (56.8)        | <0.001  |
| AST, IU/mL                 | 75 ± 133.6     | 76.4 ± 131.8      | 83.8 ± 121.7      | <0.001  |
| ALT, IU/mL                 | 80.5 ± 165.6   | 84.4 ± 165.7      | 105.1 ± 165.3     | <0.001  |
| Total bilirubin, mg/dL     | 1.1 ± 1.9      | 1.1 ± 1.9         | 1.0 ± 1.5         | <0.001  |
| Albumin, g/dL              | 4 ± 0.6        | 4.0 ± 0.6         | 4.1 ± 0.5         | <0.001  |
| Platelet count, 10^3/mL    | 178.8 ± 81.3   | 178.9 ± 78.6      | 179.4 ± 62.9      | <0.001  |

Data were reported as mean ± standard deviation or no. (%).

**Abbreviations**: ETV, entecavir; TAF, tenofovir alafenamie; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase

Table 2. Risk factors for the development of hepatocellular carcinoma
| Variables                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | P-value             | Adjusted HR | 95% CI    | P-value |
| Male                            | <0.001              | 3.796       | 2.159~6.674 | <0.001 |
| Diabetes                        | 0.049               | 0.831       | 0.491~1.407 | 0.491   |
| Hypertension                    | <0.001              | 3.042       | 1.935~4.783 | <0.001 |
| Liver cirrhosis                 | 0.003               | 1.801       | 1.184~2.739 | 0.006   |
| HBeAg positivity                | 0.931               | -          | -          | -       |
| FIB-4 index                     | <0.001              | 1.084       | 1.029~1.142 | 0.002   |
| Total bilirubin, mg/dL          | 0.438               | -          | -          | -       |
| Albumin, g/dL                   | 0.018               | 0.954       | 0.633~1.438 | 0.823   |
| TAF group (vs. ETV group)       | 0.255               | -          | -          | -       |

Abbreviations: HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TAF, tenofovir alafenamide; ETV, entecavir
Table 3. Comparison of baseline characteristics between two groups after PS matching

| Variables              | Total (N=570) | ETV group (N=285) | TAF group (N=285) | p-value |
|------------------------|---------------|-------------------|-------------------|---------|
| Age, years             | 50.7 ± 11.2   | 50.1 ± 11.3       | 49.5 ± 11.4       | 0.304   |
| Male, no. (%)          | 336 (58.9)    | 166 (58.2)        | 170 (59.6)        | 0.733   |
| Diabetes               | 51 (8.9)      | 24 (8.4)          | 27 (9.5)          | 0.660   |
| Hypertension           | 85 (14.9)     | 38 (13.3)         | 47 (16.5)         | 0.290   |
| Liver cirrhosis        | 197 (34.6)    | 101 (35.4)        | 96 (33.7)         | 0.660   |
| HBeAg positivity       | 321 (56.3)    | 159 (55.8)        | 162 (56.8)        | 0.800   |
| AST, IU/mL             | 82.4 ± 152.4  | 83.1 ± 137.8      | 83.8 ± 121.7      | <0.001  |
| ALT, IU/mL             | 103.9 ± 208.7 | 104.5 ± 188.1     | 105.1 ± 165.3     | <0.001  |
| Total bilirubin, mg/dL | 0.9 ± 0.8     | 1 ± 1.2           | 1 ± 1.5           | 0.187   |
| Albumin, g/dL          | 4.1 ± 0.5     | 4.1 ± 0.5         | 4.1 ± 0.5         | 0.877   |
| Platelet count, 10^3/mL| 170.5 ± 68.1  | 174.9 ± 65.6      | 179.4 ± 62.9      | 0.028   |

Data were reported as mean ± standard deviation or no. (%).

**Abbreviations:** PS, propensity score; ETV, entecavir; TAF, tenofovir alafenamide; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase
### Table 4. Comparison of baseline characteristics between two groups after ITPW

| Variables                  | Total   | ETV group | TAF group | p-value |
|----------------------------|---------|-----------|-----------|---------|
| Age, years                 | 52.8 ± 11.3 | 52.8 ± 14.1 | 52.9 ± 24.1 | <0.001  |
| Male, no. (%)              | 1780.6 (58.9) | 915 (60)  | 865.6 (57.8) | 0.226   |
| Diabetes                   | 546.8 (18.1) | 274 (18)   | 272.8 (18.2) | 0.853   |
| Hypertension               | 718.8 (23.8) | 356 (23.3) | 362.8 (24.2) | 0.564   |
| Liver cirrhosis            | 931.1 (30.8) | 443 (29)   | 488.1 (32.6) | 0.034   |
| HBeAg positivity           | 1037.5 (34.3) | 523 (34.3) | 514.5 (34.4) | 0.962   |
| AST, IU/mL                 | 75 ± 133.6  | 81.5 ± 164.4 | 88.2 ± 275.7 | <0.001  |
| ALT, IU/mL                 | 80.5 ± 165.6 | 90.6 ± 209.6 | 100.9 ± 362.8 | <0.001  |
| Total bilirubin, mg/dL     | 1.1 ± 1.9   | 1.1 ± 2.4  | 1.1 ± 4.2  | 0.040   |
| Albumin, g/dL              | 4 ± 0.6     | 4 ± 0.7    | 4 ± 1.2    | 0.001   |
| Platelet count, ´ 10^3/mL  | 178.8 ± 81.3 | 175.2 ± 95 | 171.6 ± 148.2 | 0.220   |

Data were reported as mean ± standard deviation or no. (%).

**Abbreviations:** IPTW, inverse probability of treatment weighting; ETV, entecavir; TAF, tenofovir alafenamide; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase

**Figures**
Figure 1

Kaplan-Meier curves of hepatocellular carcinoma (HCC) development between the two groups

Figure 2
Kaplan-Meier curves of hepatocellular carcinoma (HCC) development between the two groups after 1:1 propensity score-matching analysis.

**Figure 3**

Kaplan-Meier curves of hepatocellular carcinoma (HCC) development between the two groups after inverse probability of treatment weighting analysis.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupFlg2.jpg
- SupFig1.jpg
- SupplementaryTable.docx